{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:16:08Z","timestamp":1792671368711,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Neurosciences"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.tins.2015.12.008","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T01:31:50Z","timestamp":1454117510000},"page":"100-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["Rett Syndrome: Crossing the Threshold to Clinical Translation"],"prefix":"10.1016","volume":"39","author":[{"given":"David M.","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Coenraads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish U.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Philpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Tarquinio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tins.2015.12.008_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1242\/dmm.011007","article-title":"Preclinical research in Rett syndrome: setting the foundation for translational success","volume":"5","author":"Katz","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.tins.2015.12.008_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110648","article-title":"MeCP2 and Rett syndrome: reversibility and potential avenues for therapy","volume":"439","author":"Gadalla","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.tins.2015.12.008_bib0020","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1172\/JCI78167","article-title":"MECP2 disorders: from the clinic to mice and back","volume":"125","author":"Lombardi","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tins.2015.12.008_bib0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pedneo.2011.08.002","article-title":"Rett syndrome: from bed to bench","volume":"52","author":"Weng","year":"2011","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.tins.2015.12.008_bib0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13311-015-0353-y","article-title":"Rett Syndrome: reaching for clinical trials","volume":"12","author":"Pozzo-Miller","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tins.2015.12.008_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neuropharm.2012.08.010","article-title":"Rett syndrome treatment in mouse models: searching for effective targets and strategies","volume":"68","author":"Ricceri","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tins.2015.12.008_bib0040","doi-asserted-by":"crossref","DOI":"10.2217\/fnl.12.79","article-title":"Recent progress in Rett Syndrome and MeCP2 dysfunction: assessment of potential treatment options","author":"Chapleau","year":"2013","journal-title":"Future Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.neuron.2007.10.001","article-title":"The story of Rett syndrome: from clinic to neurobiology","volume":"56","author":"Chahrour","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.tins.2015.12.008_bib0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jpeds.2005.10.037","article-title":"Rett syndrome in Australia: a review of the epidemiology","volume":"148","author":"Laurvick","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.tins.2015.12.008_bib0055","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","article-title":"Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome","volume":"70","author":"Neul","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.tins.2015.12.008_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mrdd.10020","article-title":"Clinical manifestations and stages of Rett syndrome","volume":"8","author":"Hagberg","year":"2002","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"10.1016\/j.tins.2015.12.008_bib0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.31887\/DCNS.2012.14.3\/jneul","article-title":"The relationship of Rett syndrome and MECP2 disorders to autism","volume":"14","author":"Neul","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0070","first-page":"723","article-title":"[On a unusual brain atrophy syndrome in hyperammonemia in childhood]","volume":"116","author":"Rett","year":"1966","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.tins.2015.12.008_bib0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1866-1955-6-20","article-title":"Developmental delay in Rett syndrome: data from the natural history study","volume":"6","author":"Neul","year":"2014","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tins.2015.12.008_bib0080","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3109\/09638288.2014.962109","article-title":"Communication intervention in Rett syndrome: a survey of speech language pathologists in Swedish health services","volume":"37","author":"Wandin","year":"2015","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.tins.2015.12.008_bib0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1073858402239591","article-title":"The neurobiology of Rett syndrome","volume":"9","author":"Akbarian","year":"2003","journal-title":"Neuroscientist"},{"key":"10.1016\/j.tins.2015.12.008_bib0090","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.tins.2015.12.008_bib0095","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.conb.2011.06.006","article-title":"Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met","volume":"21","author":"Shepherd","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.tins.2015.12.008_bib0100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/08830738050200082401","article-title":"Neuropathology of Rett syndrome","volume":"20","author":"Armstrong","year":"2005","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2009.05.001","article-title":"Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations","volume":"35","author":"Chapleau","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2015.12.008_bib0110","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1073\/pnas.0912257106","article-title":"Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities","volume":"106","author":"Samaco","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-2007-979740","article-title":"Neurobiology of Rett syndrome","volume":"26","author":"Johnston","year":"1995","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.tins.2015.12.008_bib0120","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1531-8249(199904)45:4<541::AID-ANA21>3.0.CO;2-2","article-title":"Development of amino acid receptors in frontal cortex from girls with Rett syndrome","volume":"45","author":"Blue","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0125","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.41.11.1753","article-title":"Altered neurochemical markers in Rett's syndrome","volume":"41","author":"Wenk","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.tins.2015.12.008_bib0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev.cellbio.24.110707.175235","article-title":"Communication between the synapse and the nucleus in neuronal development, plasticity, and disease","volume":"24","author":"Cohen","year":"2008","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.tins.2015.12.008_bib0135","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1093\/hmg\/dds208","article-title":"Postnatal inactivation reveals enhanced requirement for MeCP2 at distinct age windows","volume":"21","author":"Cheval","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0140","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1206593","article-title":"Adult neural function requires MeCP2","volume":"333","author":"McGraw","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.tins.2015.12.008_bib0145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.conb.2012.03.009","article-title":"Astrocytes conspire with neurons during progression of neurological disease","volume":"22","author":"McGann","year":"2012","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.tins.2015.12.008_bib0150","doi-asserted-by":"crossref","first-page":"13529","DOI":"10.1523\/JNEUROSCI.3077-12.2012","article-title":"A critical and cell-autonomous role for MeCP2 in synaptic scaling up","volume":"32","author":"Blackman","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0155","doi-asserted-by":"crossref","first-page":"11263","DOI":"10.1523\/JNEUROSCI.1019-09.2009","article-title":"Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome","volume":"29","author":"Dani","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0160","doi-asserted-by":"crossref","first-page":"12187","DOI":"10.1523\/JNEUROSCI.3156-09.2009","article-title":"Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome","volume":"29","author":"Taneja","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0165","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1038\/ncomms6036","article-title":"Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity","volume":"5","author":"He","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tins.2015.12.008_bib0170","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1523\/JNEUROSCI.2159-12.2012","article-title":"Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment","volume":"32","author":"Kron","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0175","doi-asserted-by":"crossref","first-page":"12560","DOI":"10.1073\/pnas.0506071102","article-title":"Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome","volume":"102","author":"Dani","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0180","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.neuron.2012.12.004","article-title":"NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2","volume":"76","author":"Durand","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.tins.2015.12.008_bib0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nbd.2010.01.018","article-title":"Synaptic circuit abnormalities of motor-frontal layer 2\/3 pyramidal neurons in a mutant mouse model of Rett syndrome","volume":"38","author":"Wood","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2015.12.008_bib0190","article-title":"Mechanisms of functional hypoconnectivity in the medial prefrontal cortex of Mecp2 null mice","author":"Sceniak","year":"2015","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.tins.2015.12.008_bib0195","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1523\/JNEUROSCI.5503-09.2010","article-title":"Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice","volume":"30","author":"Kline","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0200","doi-asserted-by":"crossref","first-page":"18208","DOI":"10.1073\/pnas.1012104107","article-title":"Correction of respiratory disorders in a mouse model of Rett syndrome","volume":"107","author":"Abdala","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hipo.22360","article-title":"Excitation\/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice","volume":"25","author":"Calfa","year":"2015","journal-title":"Hippocampus"},{"key":"10.1016\/j.tins.2015.12.008_bib0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hipo.20389","article-title":"The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability","volume":"18","author":"Zhang","year":"2008","journal-title":"Hippocampus"},{"key":"10.1016\/j.tins.2015.12.008_bib0215","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1073\/pnas.0401626101","article-title":"Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice","volume":"101","author":"Luikenhuis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0220","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/444549","article-title":"Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males","volume":"77","author":"Van Esch","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0225","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.gim.0000250502.28516.3c","article-title":"Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males","volume":"8","author":"del Gaudio","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.tins.2015.12.008_bib0230","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/jmg.2004.023804","article-title":"Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome","volume":"42","author":"Meins","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0235","doi-asserted-by":"crossref","first-page":"02676","DOI":"10.7554\/eLife.02676","article-title":"Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice","volume":"3","author":"Heckman","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.tins.2015.12.008_bib0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature10726","article-title":"Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons","volume":"481","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tins.2015.12.008_bib0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.tins.2015.12.008_bib0250","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.mce.2011.11.007","article-title":"Evolution and roles of stanniocalcin","volume":"349","author":"Yeung","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tins.2015.12.008_bib0255","doi-asserted-by":"crossref","first-page":"12591","DOI":"10.1073\/pnas.1413620111","article-title":"Genetic and pharmacological reactivation of the mammalian inactive X chromosome","volume":"111","author":"Bhatnagar","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0260","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tins.2015.12.008_bib0265","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tins.2015.12.008_bib0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tins.2015.12.008_bib0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mt.2012.200","article-title":"Improved survival and reduced phenotypic severity following AAV9\/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice","volume":"21","author":"Gadalla","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tins.2015.12.008_bib0280","doi-asserted-by":"crossref","first-page":"13612","DOI":"10.1523\/JNEUROSCI.1854-13.2013","article-title":"Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome","volume":"33","author":"Garg","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0285","article-title":"Advances in therapeutic CRISPR\/Cas9 genome editing","author":"Savic","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.tins.2015.12.008_bib0290","article-title":"To edit or not to edit: regulation of ADAR editing specificity and efficiency","author":"Deffit","year":"2015","journal-title":"RNA"},{"key":"10.1016\/j.tins.2015.12.008_bib0295","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0300","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00109-010-0704-4","article-title":"Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model","volume":"89","author":"Brendel","year":"2011","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.tins.2015.12.008_bib0305","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/FBP.0b013e32830c3645","article-title":"Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches","volume":"19","author":"Ricceri","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.tins.2015.12.008_bib0310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.resp.2013.06.022","article-title":"Breathing challenges in Rett Syndrome: lessons learned from humans and animal models","volume":"189","author":"Ramirez","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.tins.2015.12.008_bib0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.resp.2009.04.017","article-title":"Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth","volume":"168","author":"Katz","year":"2009","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.tins.2015.12.008_bib0320","article-title":"Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett Syndrome phenotype","author":"Patrizi","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tins.2015.12.008_bib0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio0208-91","article-title":"Losing inhibition with ketamine","volume":"4","author":"Seamans","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tins.2015.12.008_bib0330","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00000542-200301000-00021","article-title":"Ketamine differentially blocks sensory afferent synaptic transmission in medial nucleus tractus solitarius (mNTS)","volume":"98","author":"Jin","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tins.2015.12.008_bib0335","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","author":"Lepack","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tins.2015.12.008_bib0340","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1176\/appi.ajp.2012.12040531","article-title":"Synaptic mechanisms underlying rapid antidepressant action of ketamine","volume":"169","author":"Kavalali","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tins.2015.12.008_bib0345","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/hmg\/ddq563","article-title":"Reduced AKT\/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model","volume":"20","author":"Ricciardi","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0350","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.biopsych.2012.11.011","article-title":"Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants","volume":"73","author":"Dwyer","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tins.2015.12.008_bib0355","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","article-title":"Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative","volume":"51","author":"Bogaerts","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tins.2015.12.008_bib0360","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.berh.2014.03.004","article-title":"Methodology of clinical trials for rare diseases","volume":"28","author":"Tudur Smith","year":"2014","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.tins.2015.12.008_bib0365","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jclinepi.2007.07.008","article-title":"Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases","volume":"61","author":"van der Lee","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.tins.2015.12.008_bib0370","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1359-6446(04)03023-5","article-title":"The advantages and disadvantages of adaptive designs for clinical trials","volume":"9","author":"Bauer","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tins.2015.12.008_bib0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-90-481-9485-8_11","article-title":"Clinical trials and rare diseases","volume":"686","author":"Gerss","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tins.2015.12.008_bib0380","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00415-013-7104-y","article-title":"Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients","volume":"260","author":"Takeuchi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0385","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/1087057115586535","article-title":"Drug discovery of therapies for Duchenne muscular dystrophy","volume":"20","author":"Blat","year":"2015","journal-title":"J. Biomol. Screen."},{"issue":"Suppl. 1","key":"10.1016\/j.tins.2015.12.008_bib0390","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1016\/S0387-7604(01)00374-6","article-title":"Rett syndrome in Spain: mutation analysis and clinical correlations","volume":"23","author":"Monros","year":"2001","journal-title":"Brain Dev."},{"key":"10.1016\/j.tins.2015.12.008_bib0395","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.870050303","article-title":"Rett syndrome and associated movement disorders","volume":"5","author":"FitzGerald","year":"1990","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tins.2015.12.008_bib0400","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jmedgenet-2013-102113","article-title":"Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome","volume":"51","author":"Cuddapah","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0405","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome","volume":"55","author":"Motil","year":"2012","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.tins.2015.12.008_bib0410","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.0b013e3181d6b852","article-title":"Epilepsy and the natural history of Rett syndrome","volume":"74","author":"Glaze","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.tins.2015.12.008_bib0415","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ana.410350415","article-title":"Rett syndrome: controlled study of an oral opiate antagonist, naltrexone","volume":"35","author":"Percy","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0420","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0883073808327827","article-title":"A study of the treatment of Rett syndrome with folate and betaine","volume":"24","author":"Glaze","year":"2009","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0425","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1073\/pnas.1311141111","article-title":"Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome","volume":"111","author":"Khwaja","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0430","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/0883073811417184","article-title":"Folinic acid supplementation in Rett syndrome patients does not influence the course of the disease: a randomized study","volume":"27","author":"Hagebeuk","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0435","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/clpt.2013.218","article-title":"Strategies for postmarketing surveillance of drugs for rare diseases","volume":"95","author":"Kesselheim","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tins.2015.12.008_bib0440","doi-asserted-by":"crossref","first-page":"e0120981","DOI":"10.1371\/journal.pone.0120981","article-title":"Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa","volume":"10","author":"Hampson","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tins.2015.12.008_bib0445","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(92)90610-O","article-title":"Purification, sequence and cellular localisation of a novel chromosomal protein that binds to methylated DNA","volume":"69","author":"Lewis","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.tins.2015.12.008_bib0450","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1093\/nar\/21.21.4886","article-title":"Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2","volume":"21","author":"Nan","year":"1993","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tins.2015.12.008_bib0455","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.molcel.2010.01.030","article-title":"Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state","volume":"37","author":"Skene","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tins.2015.12.008_bib0460","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.cell.2013.03.011","article-title":"Methylation-dependent and -independent genomic targeting principles of the MBD protein family","volume":"153","author":"Baubec","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tins.2015.12.008_bib0465","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nn.3607","article-title":"Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain","volume":"17","author":"Guo","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature14319","article-title":"Disruption of DNA-methylation-dependent long gene repression in Rett syndrome","volume":"522","author":"Gabel","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.tins.2015.12.008_bib0475","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.1169786","article-title":"The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain","volume":"324","author":"Kriaucionis","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.tins.2015.12.008_bib0480","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1093\/nar\/gkh739","article-title":"Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2)","volume":"32","author":"Valinluck","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tins.2015.12.008_bib0485","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1101\/gad.2037511","article-title":"CpG islands and the regulation of transcription","volume":"25","author":"Deaton","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.tins.2015.12.008_bib0490","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1073\/pnas.1505909112","article-title":"MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tins.2015.12.008_bib0495","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1021\/bi0001271","article-title":"Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA","volume":"39","author":"Ballestar","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.tins.2015.12.008_bib0500","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nn.3434","article-title":"Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR\/SMRT co-repressor","volume":"16","author":"Lyst","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tins.2015.12.008_bib0505","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrg3897","article-title":"Rett syndrome: a complex disorder with simple roots","volume":"16","author":"Lyst","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0510","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81887-5","article-title":"MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin","volume":"88","author":"Nan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.tins.2015.12.008_bib0515","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/30764","article-title":"Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex","volume":"393","author":"Nan","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tins.2015.12.008_bib0520","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/hmg\/ddp181","article-title":"Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus","volume":"18","author":"Ben-Shachar","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0525","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.1153252","article-title":"MeCP2, a key contributor to neurological disease, activates and represses transcription","volume":"320","author":"Chahrour","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.tins.2015.12.008_bib0530","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.stem.2013.09.001","article-title":"Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons","volume":"13","author":"Li","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tins.2015.12.008_bib0535","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/stem.1180","article-title":"Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons","volume":"30","author":"Yazdani","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.tins.2015.12.008_bib0540","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.devcel.2014.01.032","article-title":"MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8\/Drosha complex","volume":"28","author":"Cheng","year":"2014","journal-title":"Dev. Cell"},{"key":"10.1016\/j.tins.2015.12.008_bib0545","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/cr.2013.110","article-title":"Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition","volume":"23","author":"Maunakea","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.tins.2015.12.008_bib0550","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng1491","article-title":"Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome","volume":"37","author":"Horike","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0555","doi-asserted-by":"crossref","first-page":"32181","DOI":"10.1074\/jbc.M305308200","article-title":"Chromatin compaction by human MeCP2: Assembly of novel secondary chromatin structures in the absence of DNA methylation","volume":"278","author":"Georgel","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tins.2015.12.008_bib0560","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.molmed.2014.03.004","article-title":"MeCP2: the long trip from a chromatin protein to neurological disorders","volume":"20","author":"Ausio","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tins.2015.12.008_bib0565","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajmg.1320250525","article-title":"Therapeutic effects of a ketogenic diet in rett syndrome","volume":"25","author":"Haas","year":"1986","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.tins.2015.12.008_bib0570","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0387-7604(12)80198-7","article-title":"A double blind trial of bromocriptine in the Rett syndrome","volume":"12","author":"Zappella","year":"1990","journal-title":"Brain Dev."},{"key":"10.1016\/j.tins.2015.12.008_bib0575","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/088307389901400306","article-title":"Rett syndrome: randomized controlled trial of L-carnitine","volume":"14","author":"Ellaway","year":"1999","journal-title":"J. Child Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.tins.2015.12.008_bib0580","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0387-7604(01)00346-1","article-title":"Medium-term open label trial of L-carnitine in Rett syndrome","volume":"23","author":"Ellaway","year":"2001","journal-title":"Brain Dev."},{"key":"10.1016\/j.tins.2015.12.008_bib0585","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.braindev.2008.05.003","article-title":"Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment","volume":"31","author":"Temudo","year":"2009","journal-title":"Brain Dev."},{"key":"10.1016\/j.tins.2015.12.008_bib0590","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/0883073810390037","article-title":"Clinical and electroencephalographic effects of folinic acid treatment in Rett syndrome patients","volume":"26","author":"Hagebeuk","year":"2011","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.tins.2015.12.008_bib0595","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/DBP.0b013e31822177a8","article-title":"Effects of creatine supplementation in Rett syndrome: a randomized, placebo-controlled trial","volume":"32","author":"Freilinger","year":"2011","journal-title":"J. Dev. Behav. Pediatr."},{"key":"10.1016\/j.tins.2015.12.008_bib0600","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1179\/1351000211Y.0000000004","article-title":"Oxidative stress in Rett syndrome: natural history, genotype, and variants","volume":"16","author":"Leoncini","year":"2011","journal-title":"Redox Rep."},{"key":"10.1016\/j.tins.2015.12.008_bib0605","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.cca.2011.04.016","article-title":"F(4)-neuroprostanes mediate neurological severity in Rett syndrome","volume":"412","author":"Signorini","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.tins.2015.12.008_bib0610","first-page":"679801","article-title":"IGF1 as a potential treatment for Rett Syndrome: safety assessment in six Rett patients","volume":"2012","author":"Pini","year":"2012","journal-title":"Autism Res. Treat."},{"key":"10.1016\/j.tins.2015.12.008_bib0615","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12263-012-0285-7","article-title":"Partial rescue of Rett syndrome by omega-3 polyunsaturated fatty acids (PUFAs) oil","volume":"7","author":"De Felice","year":"2012","journal-title":"Genes Nutr."},{"key":"10.1016\/j.tins.2015.12.008_bib0620","doi-asserted-by":"crossref","first-page":"983178","DOI":"10.1155\/2014\/983178","article-title":"Effects of omega-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome","volume":"2014","author":"Maffei","year":"2014","journal-title":"Mediators of Inflamm."}],"container-title":["Trends in Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166223615002829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166223615002829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T20:25:57Z","timestamp":1654201557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166223615002829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0166223615002829"],"URL":"https:\/\/doi.org\/10.1016\/j.tins.2015.12.008","relation":{},"ISSN":["0166-2236"],"issn-type":[{"value":"0166-2236","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rett Syndrome: Crossing the Threshold to Clinical Translation","name":"articletitle","label":"Article Title"},{"value":"Trends in Neurosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tins.2015.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}